Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds

Bottomley, David; Ash, D.; Al-Qaisieh, B.; Carey, B.; Joseph, Joji; Clair, Shaun St; Gould, Kathy

doi:10.1016/j.radonc.2006.11.006

Cited by 58 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…worse toxicity, whereas it was not significantly associated with acute RTOG Grade 3 toxicity. Our median interval to IPSS resolution was 6 months and shorter than several reports (Williams et al 2004;Keyes et al 2009), or comparable to others (Ohashi et al 2006;Bottomley et al 2007;Anderson et al 2009). The short interval may be associated with our lower incidence of severe AUT, compared with the findings of other reports (Williams et al 2004;Keyes et al 2009).…”

Section: Discussionsupporting

confidence: 90%

Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Takeda

Jingu

Koto

et al. 2011

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Prostate cancer is one of the common cancers in the world. In Japan, prostate brachytherapy (PB) with iodine-125 has become a treatment option for localized prostate cancer since 2003. Nevertheless, severe acute urinary toxicity (AUT) remains as one of the intractable side effects. We assessed AUT and the changes in international prostate symptom score (IPSS) before and after PB for localized prostate cancer. IPSS is a questionnaire tool for tracking the subjective urinary symptoms. Between 2006 and 2009, 104 eligible patients underwent PB with iodine-125 were analyzed. AUT was graded with the radiation therapy oncology group (RTOG) scale. Eligible patients filled out IPSS questionnaires before and after PB. Clinical and treatment-related factors were examined for correlation with the severity of AUT and the interval to IPSS resolution. AUT of RTOG Grade 0 (no changes) and Grade 2 was detected in one and 96 patients, respectively, whereas seven patients (6.7%) experienced AUT of Grade 3. Thus, the incidence of severe AUT (Grade 3) after PB was low. A greater number of needles ( p = 0.012) were associated with AUT of RTOG Grade 3 on the univariate analysis. The median interval to IPSS resolution was 6 months (7 ± 6 months). Greater post-implant maximal IPSS ( p < 0.001) was associated with slower IPSS resolution, whereas higher pre-implant IPSS ( p < 0.001) was associated with faster IPSS resolution on the multivariate analysis. In conclusion, reducing the number of needles in PB may be helpful for decreasing the rate of severe AUT.

show abstract

Section: Discussionsupporting

confidence: 90%

Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Takeda

Jingu

Koto

et al. 2011

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…So we stratified preimplant IPSS into mild (0-7), moderate (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19), and severe (20-35) categories and further analyzed preimplant IPSS values of the three categories. The IPSS variations between different groups were shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

Fang

Cooperberg

et al. 2013

World J Urol

View full text Add to dashboard Cite

Objective To investigate variation in the International Prostate Symptom Score (IPSS) in men following prostate brachytherapy.Methods From January 2004 to November 2009, 524 consecutive patients underwent prostate brachytherapy either alone or in combination with external beam radiation therapy for T1c-T3b prostate cancer. The IPSS was assessed preimplant and at 1, 6, 12, 24, 36, and 48 months after treatment. Clinical and treatment-related factors were assessed for correlations with the IPSS increase. Results The mean preimplant IPSS was 7.4, with the greatest mean score of 16.0 at 1 month. At 6 months, the mean total IPSS had decreased to 11.5, but it was still statistically significantly greater than that at baseline (\0.001). At 12 months, the IPSS was decreased to 8.6, slightly greater than baseline (p = 0.001). The IPSS of 45.4 % (69/152) patients gradually returned to preimplant levels and that of 71.1 % (108/152) patients returned to within 3 points of the baseline at 24 months. At 24, 36, and 48 months after seed implantation, the IPSS was 8.6, 7.7, and 8.2, respectively, and none of these values differed statistically significantly from baseline (p [ 0.05). Sixteen patients (3.1 %) showed AUR, and 11 patients required catheterization. On univariate and multivariate analyses, the IPSS increase was best predicted by lower preimplant IPSS. Conclusion In our series, IPSS after prostate brachytherapy peaked at 1 month and gradually returned to approximately baseline at 24 months. The IPSS increase was best predicted by lower preimplant IPSS.

show abstract

“…13,14 Similarly, brachytherapy seed visualization with photoacoustic imaging 11,[15][16][17][18] has the potential to reduce the 13 to 61% dose deviation errors caused by typical seed placement errors, 19,20 thereby mitigating the risks of urinary and rectal side effects. [21][22][23] Advanced photoacoustic imaging methods that incorporate contrast agents, [24][25][26] frequency-domain analyses, 27 or coherence-based beamforming 28 offer promising access to additional molecular, structural, or quantitative tissue information for early-stage prostate cancer detection or more effective brachytherapy administration.…”

Section: Introductionmentioning

confidence: 99%

Transurethral light delivery for prostate photoacoustic imaging

et al. 2015

View full text Add to dashboard Cite

Abstract. Photoacoustic imaging has broad clinical potential to enhance prostate cancer detection and treatment, yet it is challenged by the lack of minimally invasive, deeply penetrating light delivery methods that provide sufficient visualization of targets (e.g., tumors, contrast agents, brachytherapy seeds). We constructed a sidefiring fiber prototype for transurethral photoacoustic imaging of prostates with a dual-array (linear and curvilinear) transrectal ultrasound probe. A method to calculate the surface area and, thereby, estimate the laser fluence at this fiber tip was derived, validated, applied to various design parameters, and used as an input to three-dimensional Monte Carlo simulations. Brachytherapy seeds implanted in phantom, ex vivo, and in vivo canine prostates at radial distances of 5 to 30 mm from the urethra were imaged with the fiber prototype transmitting 1064 nm wavelength light with 2 to 8 mJ pulse energy. Prebeamformed images were displayed in real time at a rate of 3 to 5 frames per second to guide fiber placement and beamformed offline. A conventional delay-and-sum beamformer provided decreasing seed contrast (23 to 9 dB) with increasing urethra-to-target distance, while the shortlag spatial coherence beamformer provided improved and relatively constant seed contrast (28 to 32 dB) regardless of distance, thus improving multitarget visualization in single and combined curvilinear images acquired with the fiber rotating and the probe fixed. The proposed light delivery and beamforming methods promise to improve key prostate cancer detection and treatment strategies.

show abstract

Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds

Cited by 58 publications

References 25 publications

Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Predicting the Severity of Acute Urinary Toxicity after Brachytherapy with Iodine-125 for Localized Prostate Cancer

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

Transurethral light delivery for prostate photoacoustic imaging

Contact Info

Product

Resources

About